Resistant Hypertension appears here as a parliamentary thread from the Lords Chamber on 24 Jun 2026, with 9 speakers contributing 18 speeches.

#Resistant Hypertension, #Renal Denervation, #NHS England, #NICE, #Department of Health and Social Care, #Cardiovascular Disease, #NHS Commissioning, #Health Prevention

Peers questioned whether NHS diagnosis rates, public awareness and trial capacity are strong enough for emerging dementia drugs, as the Government pointed to £555m in recent research funding, work to restore the 66.7% diagnosis target, a new frailty and dementia framework by year end, and NICE reviews of two Alzheimer’s treatments.

Lords speakers warned that people with severe ME face patchy NHS support and a wait until at least April 2027 for decisions on specialist services; the Government said its ME/CFS delivery plan is under way, with a progress update due next month, research funding in place, and interim support for the most serious cases still being considered.

Peers warned that charging VAT on medicines donated through compassionate use and early-access schemes could reduce access for patients with rare cancers and other serious conditions; the Government said the tax treatment is long-standing, promised to work with HMRC, companies and charities on a quick patient-focused solution, but gave no figures on patients affected or revenue expected.